WESTFORD, Mass., March 15, 2011 /PRNewswire/ -- Cynosure, Inc. (Nasdaq: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that two of its newest workstations for laser-assisted lipolysis and non-invasive cellulite reduction have received key international regulatory clearances.
Health Canada has issued a Medical Device License authorizing the sale in Canada of the company's SmoothShapes® XV system for the temporary reduction in the appearance of cellulite. The non-invasive SmoothShapes XV treats cellulite through a proprietary process known as Photomology®, which combines laser and light energy with mechanical manipulation (vacuum and massage) to produce tighter, smoother-looking skin.
Overseas, the Korea Food and Drug Administration has granted marketing approval to Cynosure's Smartlipo Triplex™, the company's minimally invasive technology for fat removal and skin tightening. The system uses Cynosure's patented MultiPlex technology to combine three wavelengths – 1064 nm, 1320 nm and 1440 nm – in one laser output. MultiPlex technology enables multiple wavelengths to be fired sequentially, creating a blended thermal and photomechanical effect that efficiently liquefies fat and tightens skin through tissue coagulation.
Cynosure plans to sell the products through its direct sales force in North America and Korea.
SmoothShapes XV and Smartlipo Triplex are also cleared for marketing in the United States by the U.S. Food and Drug Administration. Additionally, SmoothShapes XV is CE marked for sale in the European Union.
"SmoothShapes XV and Smartlipo Triplex are treatments that we believe deliver a superior outcome for the high-volume aesthetic applications they serve," said Michael Davin, president and chief executive officer of Cynosure. "The Cynosure brand is well established in Canada and Korea, and these clearances represent incremental growth opportunities. We are delighted to bring two of our newest workstations to these attractive markets."
About Cynosure, Inc.Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.
Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.Contact:Scott SolomonVice PresidentSharon Merrill Associates, Inc. Phone: (617) email@example.com
|SOURCE Cynosure, Inc.|
Copyright©2010 PR Newswire.
All rights reserved